Turnstone Biologics Inc., a Toronto, Ontario, Canada-based developer of novel oncolytic viral immunotherapies, completed an $11.3m Series A financing round.
The round was led by Versant Ventures with follow-on capital committed in excess of $20.0m, with participation from founding investor FACIT. In conjunction with this investment, Versant Partner Jerel Davis, PhD and Managing Director Brad Bolzon, PhD, joined Turnstone’s board.
Co-founded by scientists Drs. John Bell, Brian Lichty and David Stojdl and now led by Sammy J. Farah, PhD, MBA, Chief Executive Officer, and Brian D. Lichty, PhD, Chief Technology Officer, whose appointments were enabled by the investment, Turnstone is focused on developing novel oncolytic viral immunotherapies. The first programs are currently in Phase I/II trials in patients with advanced or metastatic solid tumours.
The company is also developing additional oncolytic virus strategies and immunotherapy combination treatments.